Ozanimod Controls MS Disease Activity Regardless of Age
WEST PALM BEACH, Fla. — Clinical and radiologic measures of disease activity remained stable or improved for relapsing multiple sclerosis (RMS) patients in all age groups over 7 to 8 years of continuous treatment with ozanimod (Zeposia). “Regardless of age category, the adjusted annualized relapse rate was below 0.2 in the phase III parent trials […]